Cebollero Ana, Puértolas Teresa, Pajares Isabel, Calera Lourdes, Antón Antonio
Department of Medical Oncology, University Hospital Miguel Servet, 50009 Zaragoza, Spain.
Mol Clin Oncol. 2016 Oct;5(4):458-462. doi: 10.3892/mco.2016.978. Epub 2016 Aug 4.
A retrospective observational study was conducted on patients diagnosed with serine/threonine-protein kinase B-Raf (BRAF)-mutated metastatic melanoma, who underwent first-line therapy with BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors (vemurafenib, dabrafenib or a combination of dabrafenib and trametinib) at the Miguel Servet University Hospital (Zaragoza, Spain) between November, 2011 and August, 2015. The aim of this study was to analyse the toxicity produced by BRAF and MEK inhibitors. The most common toxicities were similar to those published in clinical trials, particularly arthralgia, alopecia and photosensitivity in the vemurafenib group; asthenia, hyperkeratosis and dry skin in the dabrafenib group; and diarrhoea and dry skin in the dabrafenib plus trametinib group. Toxicities that had not been described in clinical trials were also identified. Thus, the present study confirmed that the results obtained in clinical trials are similar to those obtained in clinical practice.
对2011年11月至2015年8月期间在西班牙萨拉戈萨米格尔·塞尔维特大学医院被诊断为丝氨酸/苏氨酸蛋白激酶B-Raf（BRAF）突变转移性黑色素瘤且接受BRAF和丝裂原活化蛋白激酶激酶（MEK）抑制剂（维莫非尼、达拉非尼或达拉非尼与曲美替尼联合用药）一线治疗的患者进行了一项回顾性观察研究。本研究的目的是分析BRAF和MEK抑制剂产生的毒性。最常见的毒性与临床试验中公布的相似，特别是维莫非尼组的关节痛、脱发和光敏反应；达拉非尼组的乏力、角化过度和皮肤干燥；达拉非尼加曲美替尼组的腹泻和皮肤干燥。还发现了临床试验中未描述的毒性。因此，本研究证实了临床试验中获得的结果与临床实践中获得的结果相似。
